日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A formula for predicting emphysema extent in combined idiopathic pulmonary fibrosis and emphysema

用于预测特发性肺纤维化合并肺气肿患者肺气肿程度的公式

Wells, Athol U; Jacob, Joseph; Sverzellati, Nicola; Cross, Gary; Barnett, Joseph; De Lauretis, Angelo; Antoniou, Katerina; Weycker, Derek; Atwood, Mark; Kirchgaessler, Klaus-Uwe; Cottin, Vincent

The 6-min walk test as a primary end-point in interstitial lung disease

6分钟步行试验作为间质性肺病的主要终点

Harari, Sergio; Wells, Athol U; Wuyts, Wim A; Nathan, Steven D; Kirchgaessler, Klaus-Uwe; Bengus, Monica; Behr, Jürgen

A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease

对家用手持式肺功能仪在间质性肺疾病诊断中的挑战、经验教训和未来方向进行综述

Maher, Toby M; Schiffman, Courtney; Kreuter, Michael; Moor, Catharina C; Nathan, Steven D; Axmann, Judit; Belloni, Paula; Bengus, Monica; Gilberg, Frank; Kirchgaessler, Klaus-Uwe; Wijsenbeek, Marlies S

Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use

吡非尼酮治疗未分类间质性肺疾病:按合并使用吗替麦考酚酯和/或既往使用皮质类固醇进行亚组分析

Kreuter, Michael; Maher, Toby M; Corte, Tamera J; Molina-Molina, Maria; Axmann, Judit; Gilberg, Frank; Kirchgaessler, Klaus-Uwe; Cottin, Vincent

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis

根据外科肺活检状态评估吡非尼酮与安慰剂治疗未分类间质性肺疾病的疗效:一项事后分析的数据

Molina-Molina, Maria; Kreuter, Michael; Cottin, Vincent; Corte, Tamera J; Gilberg, Frank; Kirchgaessler, Klaus-Uwe; Axmann, Judit; Maher, Toby M

Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry

真实世界中特发性肺纤维化患者人群的生活质量和医疗资源利用情况:PROOF 注册研究

Wuyts, Wim A; Dahlqvist, Caroline; Slabbynck, Hans; Schlesser, Marc; Gusbin, Natacha; Compere, Christophe; Maddens, Sofie; Rizzo, Shemra; Kirchgaessler, Klaus-Uwe; Bartley, Karen; Bondue, Benjamin

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis

单核细胞计数作为特发性肺纤维化患者的预后生物标志物

Kreuter, Michael; Lee, Joyce S; Tzouvelekis, Argyrios; Oldham, Justin M; Molyneaux, Philip L; Weycker, Derek; Atwood, Mark; Kirchgaessler, Klaus-Uwe; Maher, Toby M

Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study

疑似间质性肺病患者诊断前后疾病行为:STARLINER 研究

Wijsenbeek, Marlies S; Bendstrup, Elisabeth; Valenzuela, Claudia; Henry, Michael T; Moor, Catharina C; Jouneau, Stéphane; Fois, Alessandro G; Moran-Mendoza, Onofre; Anees, Syed; Mirt, Mirela; Bengus, Monica; Gilberg, Frank; Kirchgaessler, Klaus-Uwe; Vancheri, Carlo

Patients' and Healthcare Professionals' Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational Survey

患者和医护人员使用吡非尼酮801毫克片剂治疗特发性肺纤维化的体验:一项多国调查

Lancaster, Lisa H; Valenzuela, Claudia; Mason, Wendi; Neurohr, Claus; Ripamonti, Elena; Kirchgaessler, Klaus-Uwe; Cottin, Vincent

A Multiplex Assay for the Stratification of Patients with Primary Central Nervous System Lymphoma Using Targeted Mass Spectrometry

使用靶向质谱法对原发性中枢神经系统淋巴瘤患者进行分层的多重检测

Daniel M Waldera-Lupa, Gereon Poschmann, Nina Kirchgaessler, Omid Etemad-Parishanzadeh, Falk Baberg, Mareike Brocksieper, Sabine Seidel, Thomas Kowalski, Anna Brunn, Aiden Haghikia, Ralf Gold, Anja Stefanski, Martina Deckert, Uwe Schlegel, Kai Stühler